A survey conducted by Gallup Center and West Health has found that most Americans are comfortable with artificial intelligence playing a role in their healthcare, provided that doctors remain in control. The same survey, however, indicates that physicians are less comfortable with AI in medical decision-making, highlighting a significant disconnect between patients and providers.
This divergence in attitudes matters because it could influence how quickly and in what form AI tools are integrated into clinical practice. If doctors are more hesitant than their patients, adoption may be slower or more cautious than patient demand might suggest. The survey results also suggest that the tasks AI can or cannot be trusted with will be the subject of increasing debate across the healthcare sector in the months to come. Those discussions are likely already taking place within sector players such as Astiva Health, a Medicare Advantage plan provider.
The findings come as AI applications in healthcare—from diagnostic support to administrative automation—continue to expand. Patient comfort with AI under physician oversight could ease acceptance of new tools, but physician skepticism may act as a counterweight. How the industry resolves this tension will affect the pace of innovation, the design of AI systems, and the nature of doctor-patient conversations about technology in care.
The survey was highlighted by BioMedWire, a communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire to reach diverse markets and demographics.
For healthcare organizations, the survey underscores the need to address physician concerns while leveraging patient openness. Clear communication about AI's role, robust oversight mechanisms, and targeted training may help bridge the gap. As AI continues to evolve, the dialogue between patients, doctors, and regulators will be critical in shaping trust and ensuring that technology enhances rather than undermines care.
The broader implications extend to investors and companies developing healthcare AI. Understanding stakeholder attitudes can inform product development and market strategies. BioMedWire's parent, IBN, also offers editorial syndication to 5,000+ outlets, press release enhancement, and social media distribution to amplify announcements. For more information on BioMedWire's offerings, visit www.BioMedWire.com.

